How to Choose Reliable Blood Collection Products: A U.S. Healthcare Purchasing Guide

Summary

• Reliable blood collection products should be evaluated for safety, regulatory compliance, specimen quality, compatibility, usability, and total cost rather than purchase price alone.
• U.S. Healthcare Providers should verify FDA status, CLIA-related performance requirements, OSHA protections, CLSI-aligned collection practices, lot traceability, and supplier continuity before placing an order.
• A structured purchasing process that includes validation, staff feedback, inventory controls, and supplier performance monitoring can reduce recollections, Needlestick Injuries, waste, delays, and unexpected costs.

Blood collection products are essential to nearly every area of American healthcare. Hospitals, physician offices, urgent care centers, outpatient laboratories, long-term care facilities, home-health organizations, and specialty clinics all depend on tubes, needles, blood collection sets, safety devices, lancets, tourniquets, specimen labels, transport materials, and related supplies. The reliability of these products affects much more than the convenience of a phlebotomist. It can influence patient safety, laboratory accuracy, turnaround time, operating costs, regulatory compliance, and the quality of clinical decisions.

The scale of laboratory medicine makes purchasing decisions especially important. The American Clinical Laboratory Association has frequently described the United States as performing billions of laboratory tests each year, with commonly cited estimates exceeding 14 billion tests annually. Even a small defect rate can therefore create a substantial number of rejected specimens, redraws, delayed diagnoses, and additional expenses. At the same time, the Occupational Safety and Health Administration has emphasized the occupational risks associated with bloodborne pathogens and Needlestick Injuries. Older national estimates cited by public health and occupational safety organizations have placed annual Needlestick Injuries among U.S. hospital workers in the hundreds of thousands.

For these reasons, Healthcare Providers should treat blood collection supplies as clinically important products rather than ordinary commodities. A lower unit price may be attractive, but it can be outweighed by poor draw performance, hemolysis, leakage, breakage, inconsistent vacuum, difficult activation of safety mechanisms, or unreliable delivery. A sound purchasing program evaluates the entire product lifecycle, from selection and validation to use, storage, documentation, disposal, and replenishment.

Start With the Intended Clinical Use

The first purchasing question is not which product is cheapest or most familiar. It is which product is appropriate for the patient population, collection setting, specimen type, and laboratory testing menu. Blood collection products are not interchangeable in every situation. A device that performs well in a hospital laboratory may be inconvenient or unsuitable in a pediatric clinic, emergency department, dialysis center, or home-collection program.

Consider the patient population

Adult patients with large, accessible veins may be successfully collected with a conventional multisample needle and evacuated tube system. Neonates, children, older adults, Oncology Patients, patients receiving dialysis, and individuals with fragile or Difficult Veins may require smaller-gauge needles, winged blood collection sets, syringe-transfer systems, capillary collection products, or low-volume tubes.

Providers should assess the number of pediatric and geriatric collections performed each month, the frequency of difficult draws, and the volume of blood required for common test panels. In neonatal and pediatric settings, reducing blood loss is particularly important because repeated collection can contribute to iatrogenic anemia. A product with a smaller draw volume may therefore offer clinical value that is not visible in the catalog price.

Match products to collection environments

Collection environments present different logistical and infection-control challenges. An inpatient hospital may need high-volume supplies delivered to multiple nursing units, while a physician office may need compact quantities with a longer shelf life. Mobile Phlebotomy teams need products that tolerate transport and variable working conditions. Emergency departments may prioritize rapid access, intuitive safety activation, and compatibility with many types of patients.

Before purchasing, organizations should document the following:

1. The types and volume of blood collections performed at each location.
2. The most frequently ordered laboratory tests and required specimen types.
3. The percentage of collections involving pediatric, geriatric, oncology, dialysis, or difficult-access patients.
4. Whether blood is collected directly into evacuated tubes, by syringe transfer, through a winged set, or by capillary method.
5. The distance and time between collection, processing, and testing.
6. The environmental conditions under which products are stored, transported, and used.

Verify Regulatory and Quality Requirements

Reliability begins with regulatory diligence. In the United States, many blood collection products are medical devices regulated by the U.S. Food and Drug Administration. The specific regulatory pathway depends on the product category, intended use, design, and claims made by the manufacturer. Purchasing teams should confirm that the product is legally marketed for its intended purpose and that the manufacturer provides appropriate documentation.

FDA status and manufacturer documentation

Healthcare Providers should request and retain relevant product information, including the product’s intended use, instructions for use, specifications, warnings, storage conditions, shelf life, and applicable regulatory documentation. Depending on the device, documentation may include a 510(k) clearance, an exemption, or another form of FDA authorization or listing. FDA clearance does not mean that every product is ideal for every laboratory Workflow, but it provides an important baseline for lawful marketing and intended-use evaluation.

Purchasers should also determine whether the manufacturer has a history of recalls, warning letters, field corrections, or repeated complaints involving the product category. A recall history does not automatically disqualify a supplier; large manufacturers may have more publicly visible activity because they sell greater volumes. However, unresolved quality problems, weak corrective actions, or poor communication during a recall should receive serious attention.

CLIA and laboratory requirements

The Clinical Laboratory Improvement Amendments establish quality requirements for laboratories performing testing on human specimens. Although CLIA does not approve every blood collection product, specimen collection is a critical part of the preanalytical phase covered by laboratory quality systems. Laboratories must be able to show that specimens are collected, identified, handled, transported, and processed in a manner that supports accurate testing.

A product change can affect Specimen Integrity even when the analyzer and test method remain unchanged. For example, changing tube materials, additives, fill volumes, needle configurations, or transfer methods may influence clotting, hemolysis, platelet activation, contamination, or analyte stability. A laboratory should therefore perform a documented assessment before converting to a new brand or product design.

OSHA bloodborne-pathogen protections

OSHA’s Bloodborne Pathogens Standard requires employers to use engineering and work-practice controls to reduce occupational exposure to blood and other potentially infectious materials. Safety-engineered needles and other sharps are central to this approach. OSHA also requires employers to consider safer medical devices when appropriate and to involve affected frontline employees in the selection and evaluation of engineering controls.

When purchasing needles, lancets, blood collection sets, and transfer devices, providers should evaluate whether the safety feature is integrated into the device, can be activated with one hand, provides a clear indication of activation, and prevents reuse after activation. A safety device that is technically compliant but difficult to use may not provide effective protection in a busy clinical environment.

UDI and traceability

The FDA’s Unique Device Identification system is designed to improve the identification of medical devices throughout distribution and use. Organizations should determine whether products carry UDI information and whether their inventory systems can capture device identifiers, lot numbers, expiration dates, and manufacturer information. Traceability becomes especially important during recalls, adverse-event investigations, or product-performance reviews.

Evaluate Specimen Quality and Preanalytical Performance

Most laboratory errors occur in the preanalytical phase, before a specimen reaches the analyzer. Industry studies have often estimated that approximately 60% to 70% of laboratory errors originate during preanalytical activities, although the exact percentage varies by study design and setting. Collection products are not responsible for every preanalytical error, but they can significantly affect hemolysis, clotting, insufficient volume, contamination, and incorrect blood-to-additive ratios.

Tube performance

Evacuated blood collection tubes should maintain consistent vacuum throughout their labeled shelf life and should fill to the volume required by the test method. Underfilled coagulation tubes are a well-known concern because the prescribed blood-to-Anticoagulant ratio may be altered. This can affect Prothrombin Time, Activated Partial Thromboplastin Time, and other coagulation results. Tubes used for serum, plasma, hematology, molecular testing, trace elements, or special chemistry may contain different additives and require distinct handling procedures.

Purchasers should ask manufacturers for data on vacuum consistency, additive uniformity, expiration dating, tube dimensions, closure integrity, and compatibility with the organization’s racks, centrifuges, Pneumatic Tube Systems, and analyzers. They should also verify whether the tube is validated for the tests performed by their laboratory rather than relying only on color-coded caps.

Hemolysis and recollection rates

Hemolysis can result from excessive suction, small needles, improper transfer from a syringe, vigorous mixing, difficult Venipuncture, transport conditions, or defective collection materials. It may interfere with chemistry tests and lead to recollection. A useful purchasing evaluation should compare hemolysis rates before and after implementation, using the organization’s own data.

Providers should establish a baseline for rejected specimens and then monitor changes in the following categories:

1. Hemolyzed specimens.
2. Clotted specimens submitted for anticoagulated testing.
3. Underfilled or overfilled tubes.
4. Leaking or broken tubes.
5. Incorrect tube types or additive contamination.
6. Insufficient quantity of specimen.
7. Unlabeled, mislabeled, or illegibly labeled specimens.
8. Specimens delayed beyond acceptable transport limits.

Even a modest reduction in rejection rates can generate significant savings. The cost of a rejected specimen includes the replacement product, staff time, patient inconvenience, additional transportation, laboratory labor, delayed treatment, and possible downstream costs associated with a missed or postponed clinical decision.

Needle and blood collection set performance

Needles should provide dependable flow without unnecessary trauma. Gauge selection involves a balance between patient comfort, collection time, specimen quality, and the test’s volume requirements. A very small needle may be appropriate in certain situations but can increase collection time or contribute to hemolysis if used incorrectly. Winged sets may improve access to small or mobile veins but typically cost more than basic straight needles.

Purchasing teams should review bevel design, tubing length, connector security, flashback visibility, rigidity, lubrication, and safety activation. They should also consider whether the product works with existing tube holders and whether the safety mechanism can be activated without changing the operator’s hand position.

Prioritize User Safety and Ergonomics

Frontline acceptance is a practical measure of product reliability. If a device is awkward, difficult to activate, or incompatible with established technique, staff may avoid using its safety feature or improvise workarounds. The resulting risk can affect both employees and patients.

Test safety devices in realistic conditions

Product demonstrations should include more than a tabletop review. Nurses, phlebotomists, medical assistants, laboratory personnel, and other affected workers should test devices under representative conditions. Evaluation should include routine Venipuncture, difficult draws, collections with gloves, use in confined spaces, and disposal after activation.

Important questions include whether the safety feature can be activated immediately after needle withdrawal, whether activation produces an audible or visual confirmation, whether the device remains stable during activation, and whether it prevents accidental exposure during transport to the sharps container. Organizations should document employee feedback as part of their OSHA-required evaluation of safer medical devices.

Reduce ergonomic strain

High-volume phlebotomy can involve repetitive hand movements, prolonged standing, awkward wrist positions, and frequent handling of small components. A product that reduces force, improves grip, or simplifies tube changes may decrease fatigue and improve consistency. Ergonomic performance is particularly relevant in large hospitals, outpatient laboratories, and blood donation environments where individual employees may perform dozens of collections during a shift.

Providers should examine packaging as well as the device itself. Excessive wrapping, difficult-to-open pouches, confusing orientation, or components that fall onto work surfaces can slow collection and increase contamination risk. Packaging should protect sterility while allowing efficient, clean access.

Assess Supplier Reliability and Supply Continuity

A clinically excellent product is not reliable if it cannot be delivered consistently. The Covid-19 pandemic exposed vulnerabilities in global medical supply chains, including dependence on limited manufacturing sites, transportation disruptions, raw-material shortages, and sudden demand increases. Blood collection tubes, swabs, personal protective equipment, and other laboratory supplies experienced significant pressure during the pandemic. Those disruptions demonstrated the importance of supplier-Risk Management.

Review manufacturing and distribution capacity

Healthcare Providers should ask where products are manufactured, whether critical components come from multiple sources, and whether the supplier maintains domestic or regional distribution capacity. They should determine whether the manufacturer has contingency plans for equipment failures, natural disasters, transportation interruptions, labor shortages, or sudden increases in demand.

Key supplier questions include:

1. What is the normal lead time, and how has it changed during previous disruptions?
2. Does the supplier maintain safety stock in the United States?
3. Are products manufactured at more than one qualified facility?
4. How are allocation decisions made during shortages?
5. What notice is provided before a product is discontinued or redesigned?
6. Can the supplier provide substitute products that have been appropriately evaluated?
7. How quickly are quality complaints and adverse events investigated?

Measure fill rates and delivery performance

Supplier performance should be measured with objective indicators. A contract can include expected fill rates, maximum back-order duration, notification requirements, delivery accuracy, response times, and escalation procedures. A provider should track the percentage of orders delivered complete and on time, the number of substitutions, back-order frequency, and the number of emergency purchases required because of supply failures.

Dual sourcing may be appropriate for high-risk products, but it should not be implemented casually. Using two products can increase Training Requirements, inventory complexity, and the possibility of collection errors. If a second source is maintained, the laboratory should validate it, clearly distinguish products, and ensure that staff understand any differences in handling or specimen requirements.

Calculate Total Cost of Ownership

Unit price is only one part of the financial analysis. A reliable blood collection product may cost more per item but reduce labor, recollection, waste, injury claims, and treatment delays. Conversely, a low-cost product may become expensive if it produces frequent rejected specimens or requires additional training and inventory buffers.

Include direct and indirect costs

A total-cost model should include the following categories:

1. Purchase price and freight charges.
2. Storage space and inventory carrying costs.
3. Product waste caused by expiration, damage, or excess packaging.
4. Training time and implementation expenses.
5. Labor associated with recollection and specimen investigation.
6. Costs associated with rejected or delayed tests.
7. Needlestick exposure evaluation, treatment, and workers’ compensation costs.
8. Emergency purchases caused by stockouts or back orders.
9. Costs of system changes, such as new holders, racks, labels, or accessories.
10. Disposal costs for sharps and regulated medical waste.

For example, assume a facility performs 200,000 blood collections annually and experiences a 2% Specimen Rejection rate. That represents 4,000 rejected specimens. If a change in products and Workflow reduces rejection to 1.5%, the facility avoids approximately 1,000 recollections each year. The financial value depends on local labor and patient-service costs, but the operational benefit may be substantial even before considering faster diagnosis and improved Patient Satisfaction.

Consider contract terms

Purchasing agreements should address price protection, volume tiers, freight, product substitutions, expiration dating, returns, recalls, quality complaints, and discontinued products. A provider should avoid accepting unusually short expiration periods unless the product will be used quickly. Contracts should also identify who is responsible for notification and replacement if a lot is recalled.

Confirm Compatibility With Existing Systems

Blood collection products function within a larger system. Tubes must fit centrifuges, analyzers, automated sorters, racks, pneumatic tube carriers, and storage systems. Needles must connect securely to holders or blood collection sets. Labels must adhere to the tube surface, remain readable after refrigeration or centrifugation, and work with barcode scanners.

Compatibility testing should include the entire Workflow rather than one isolated step. A tube may fit a centrifuge but fail in an automated line. A label may adhere initially but peel during transport. A holder may connect to a needle but create excessive dead space when used with a syringe. These issues can be identified through a controlled evaluation involving laboratory, nursing, information technology, materials management, and infection-prevention representatives.

Electronic identification is also important. The Centers for Medicare and Medicaid Services and laboratory accreditation organizations expect effective patient and specimen identification processes. Products should support the organization’s barcode policy, bedside labeling procedures, and electronic health record Workflow. Color coding can assist recognition, but it should never replace positive patient identification or barcode verification.

Review Storage, Shelf Life, and Inventory Controls

Blood collection products may be sensitive to temperature, humidity, light, or physical damage. Manufacturers’ storage instructions should be followed, and receiving staff should inspect shipments for crushed cartons, broken tubes, wet packaging, missing labels, and temperature concerns. Products should be stored using first-expire, first-out rotation, with expiration dates visible to staff.

Inventory systems should establish minimum and maximum levels based on normal usage, seasonal patterns, supplier lead times, and emergency reserves. Overstocking can cause expiration and tie up capital, while inadequate inventory can force substitutions or cancelations. Demand forecasting should account for influenza season, changes in clinic volume, new testing programs, public health events, and local outbreaks.

Organizations should separate quarantined, recalled, expired, and approved stock. Lot numbers should be recorded when practical, especially for products associated with specialized testing or high clinical risk. Periodic cycle counts can identify Discrepancies before they become stockouts.

Use a Formal Product Evaluation Process

A formal evaluation is safer than an informal decision based on a sales presentation or a single user’s preference. The evaluation team should include representatives from laboratory medicine, phlebotomy, nursing, infection prevention, occupational health, Supply Chain, finance, quality, and clinical leadership. Larger organizations may also include Risk Management and information technology.

Define measurable acceptance criteria

Before testing a product, the team should define what success means. Criteria might include a maximum hemolysis rate, a target Specimen Rejection rate, a minimum safety-device activation rate, an acceptable delivery fill rate, and a required shelf life upon receipt. The team should also define conditions under which the product will not be approved.

A useful evaluation may include:

1. Review of regulatory and manufacturer documentation.
2. Inspection of packaging, sterility, labeling, and expiration dates.
3. Bench testing for fit, vacuum, tube filling, and device operation.
4. Limited clinical testing in representative departments.
5. Staff surveys and direct observation of technique.
6. Comparison of Specimen Rejection and hemolysis data.
7. Review of delivery performance and customer service.
8. Final approval through the organization’s quality or value-analysis committee.

Plan implementation and training

Even a reliable product can fail if staff do not understand how it differs from the previous product. Training should cover tube types, order of draw, fill requirements, mixing instructions, safety activation, specimen labeling, transport, and disposal. The Clinical and Laboratory Standards Institute publishes widely used guidance on venous and Capillary Blood Collection, order of draw, and specimen handling. Organizations should align procedures with current applicable guidance and their laboratory’s validated methods.

Training should be provided before the conversion date and reinforced through competency checks, quick-reference materials, and supervisor observation. During the first weeks after implementation, leaders should monitor questions, rejected specimens, safety incidents, and product complaints more frequently than usual.

Monitor Performance After Purchase

Purchasing is not complete when the first shipment arrives. Providers should continuously evaluate whether the product performs as expected. Useful quality indicators include Specimen Rejection rate per 1,000 collections, hemolysis rate, recollection rate, needlestick incidents, safety-feature activation compliance, product defects, back-order frequency, and inventory expiration.

Data should be reviewed by location and user group. A product may perform well in one department but poorly in another because of differences in patient population, training, equipment, or Workflow. For example, a tube may show few problems in an outpatient laboratory but produce more underfilled specimens in an emergency department where collection conditions are less predictable.

Feedback should be documented through a standardized complaint process. Staff should know how to report cracked tubes, defective needles, missing safety components, unusual resistance, poor vacuum, leakage, or packaging problems. Product complaints should include the manufacturer, catalog number, lot number, expiration date, location, date of use, and a description of the event. This information helps the organization identify patterns and supports communication with the supplier or FDA when appropriate.

Address Sustainability and Waste

Environmental considerations are increasingly relevant in healthcare purchasing. Blood collection generates plastic packaging, used sharps, contaminated materials, and sometimes expired inventory. Sustainability, however, must never compromise infection prevention or product performance.

Providers should compare packaging volume, recyclable materials where permitted, shipping efficiency, product shelf life, and the likelihood of expiration. They should also review whether a product’s packaging is unnecessarily oversized or contains components that are routinely discarded unused. Waste reduction can lower disposal expenses and support institutional sustainability goals.

Reusable equipment, such as certain Tourniquet systems or collection trays, should be considered only when cleaning, disinfection, and infection-control requirements can be met consistently. Single-use items remain appropriate when they provide a meaningful infection-prevention advantage or when reprocessing is impractical.

Common Purchasing Mistakes to Avoid

Choosing solely on price

The lowest bid may not represent the lowest total cost. Providers should compare cost per successful collection, not merely cost per needle or tube. A slightly higher-priced product may be financially preferable if it reduces redraws, injuries, or waste.

Skipping local validation

Manufacturer claims and experience at another facility are useful, but they do not replace local evaluation. Differences in analyzers, transport systems, staff technique, and patient mix can change outcomes.

Ignoring change management

Replacing familiar products without sufficient notice can create confusion, incorrect tube selection, and resistance from frontline employees. Staff involvement should begin early, and conversion plans should provide clear timelines and escalation channels.

Failing to maintain contingency plans

Supply disruptions can occur even with established vendors. Organizations should identify critical products, define acceptable alternatives, maintain reasonable reserve stock, and periodically test their emergency procurement process. Alternatives must be evaluated before an emergency whenever possible.

Building a Reliable Purchasing Policy

A strong purchasing policy combines clinical, operational, financial, and regulatory requirements. It should identify who can approve new products, what documentation is required, how products are validated, how substitutions are controlled, and how performance is monitored. The policy should also specify how recalls, shortages, complaints, and product discontinuations are communicated.

For high-volume or high-risk supplies, providers may benefit from a scorecard. Categories can include clinical performance, patient and employee safety, regulatory documentation, supply continuity, total cost, compatibility, sustainability, and service quality. Each category can receive a weighted score based on organizational priorities. A product that scores well across all categories is more likely to provide dependable long-term value than one selected through price comparison alone.

Ultimately, reliable blood collection products are those that work consistently in the hands of trained staff, protect patients and employees, preserve specimen quality, integrate with existing systems, and remain available when needed. U.S. Healthcare Providers should combine evidence, frontline experience, supplier due diligence, and ongoing performance data before making purchasing decisions. This approach supports safer collections, more accurate laboratory results, better use of healthcare resources, and stronger resilience across the entire diagnostic process.

Disclaimer: The content provided on this blog is for informational purposes only, reflecting the personal opinions and insights of the author(s) on the topics. The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician. Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. No contributors to this web site make any representations, express or implied, with respect to the information provided herein or to its use. While we strive to share accurate and up-to-date information, we cannot guarantee the completeness, reliability, or accuracy of the content. The blog may also include links to external websites and resources for the convenience of our readers. Please note that linking to other sites does not imply endorsement of their content, practices, or services by us. Readers should use their discretion and judgment while exploring any external links and resources mentioned on this blog.

Related Videos